These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34734785)

  • 1. Polymorphism in exercise genes and respiratory function in late-onset Pompe disease.
    Ravaglia S; Malovini A; Cirio S; Danesino C; De Filippi P; Moggio M; Mongini T; Maggi L; Servidei S; Vianello A; Toscano A; Tonin P; Maioli MA; Parini R; Filosto M; Crescimanno G; Arceri S; Piran M; Carlucci A
    J Appl Physiol (1985); 2021 Dec; 131(6):1762-1771. PubMed ID: 34734785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis?
    Ravaglia S; De Filippi P; Pichiecchio A; Ponzio M; Saeidi Garaghani K; Poloni GU; Bini P; Danesino C
    Mol Genet Metab; 2012 Sep; 107(1-2):104-10. PubMed ID: 22704482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of selected polymorphisms in determining muscle fiber composition in Japanese men and women.
    Kumagai H; Tobina T; Ichinoseki-Sekine N; Kakigi R; Tsuzuki T; Zempo H; Shiose K; Yoshimura E; Kumahara H; Ayabe M; Higaki Y; Yamada R; Kobayashi H; Kiyonaga A; Naito H; Tanaka H; Fuku N
    J Appl Physiol (1985); 2018 May; 124(5):1377-1384. PubMed ID: 29345962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
    Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE I/D and ACTN3 R/X polymorphisms as potential factors in modulating exercise-related phenotypes in older women in response to a muscle power training stimuli.
    Pereira A; Costa AM; Izquierdo M; Silva AJ; Bastos E; Marques MC
    Age (Dordr); 2013 Oct; 35(5):1949-59. PubMed ID: 22855367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
    J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
    Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
    PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation in Pompe disease, a step forward.
    De Filippi P; Saeidi K; Ravaglia S; Dardis A; Angelini C; Mongini T; Morandi L; Moggio M; Di Muzio A; Filosto M; Bembi B; Giannini F; Marrosu G; Rigoldi M; Tonin P; Servidei S; Siciliano G; Carlucci A; Scotti C; Comelli M; Toscano A; Danesino C
    Orphanet J Rare Dis; 2014 Aug; 9():102. PubMed ID: 25103075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training.
    Erskine RM; Williams AG; Jones DA; Stewart CE; Degens H
    Scand J Med Sci Sports; 2014 Aug; 24(4):642-8. PubMed ID: 23384112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
    Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
    Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACTN3 genotype and modulation of skeletal muscle response to exercise in human subjects.
    Norman B; Esbjörnsson M; Rundqvist H; Österlund T; Glenmark B; Jansson E
    J Appl Physiol (1985); 2014 May; 116(9):1197-203. PubMed ID: 24651987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
    Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
    Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human angiotensin-converting enzyme I/D and alpha-actinin 3 R577X genotypes and muscle functional and contractile properties.
    McCauley T; Mastana SS; Hossack J; Macdonald M; Folland JP
    Exp Physiol; 2009 Jan; 94(1):81-9. PubMed ID: 18676575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE and ACTN3 genes and muscle phenotypes in nonagenarians.
    Bustamante-Ara N; Santiago C; Verde Z; Yvert T; Gómez-Gallego F; Rodríguez-Romo G; González-Gil P; Serra-Rexach JA; Ruiz JR; Lucia A
    Int J Sports Med; 2010 Apr; 31(4):221-4. PubMed ID: 20148371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE I/D, ACTN3 R577X, PPARD T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in Taiwanese late adolescent girls.
    Chiu LL; Chen TW; Hsieh SS; Hsieh LL
    J Physiol Sci; 2012 Mar; 62(2):115-21. PubMed ID: 22247001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
    Sechi A; Salvadego D; Da Ponte A; Bertin N; Dardis A; Cattarossi S; Devigili G; Reccardini F; Bembi B; Grassi B
    Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single and combined influence of ACE and ACTN3 genotypes on muscle phenotypes in octogenarians.
    Garatachea N; Fiuza-Luces C; Torres-Luque G; Yvert T; Santiago C; Gómez-Gallego F; Ruiz JR; Lucia A
    Eur J Appl Physiol; 2012 Jul; 112(7):2409-20. PubMed ID: 22045415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.